180 Wealth Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.58M | Sell |
17,457
-305
| -2% | -$25.6K | 0.16% | 141 |
|
|
2026
Q1 | $1.42M | Buy |
17,762
+110
| +0.6% | +$9.07K | 0.16% | 140 |
|
|
2025
Q4 | $1.5M | Sell |
17,652
-273
| -2% | -$22.4K | 0.17% | 125 |
|
|
2025
Q3 | $1.39M | Sell |
17,925
-1,200
| -6% | -$93.8K | 0.17% | 124 |
|
|
2025
Q2 | $1.5M | Sell |
19,125
-968
| -5% | -$72.2K | 0.21% | 110 |
|
|
2025
Q1 | $1.46M | Sell |
20,093
-65
| -0.3% | -$4.65K | 0.23% | 105 |
|
|
2024
Q4 | $1.49M | Sell |
20,158
-32
| -0.2% | -$2.24K | 0.23% | 97 |
|
|
2024
Q3 | $1.33M | Buy |
20,190
+9,975
| +98% | +$725K | 0.21% | 103 |
|
|
2024
Q2 | $948K | Buy |
10,215
+91
| +0.9% | +$8.06K | 0.15% | 129 |
|
|
2024
Q1 | $967K | Buy |
10,124
+183
| +2% | +$15.4K | 0.17% | 121 |
|
|
2023
Q4 | $751K | Sell |
9,941
-1,692
| -15% | -$118K | 0.15% | 136 |
|
|
2023
Q3 | $806K | Buy |
11,633
+1,357
| +13% | +$109K | 0.18% | 121 |
|
|
2023
Q2 | $940K | Sell |
10,276
-1,269
| -11% | -$110K | 0.21% | 116 |
|
|
2023
Q1 | $955K | Buy |
11,545
+598
| +5% | +$47K | 0.22% | 110 |
|
|
2022
Q4 | $856K | Buy |
10,947
+542
| +5% | +$41.8K | 0.2% | 112 |
|
|
2022
Q3 | $860K | Sell |
10,405
-81
| -0.8% | -$7.79K | 0.24% | 98 |
|
|
2022
Q2 | $1.02M | Buy |
10,486
+87
| +0.8% | +$9.01K | 0.26% | 98 |
|
|
2022
Q1 | $1.29M | Buy |
10,399
+71
| +0.7% | +$7.96K | 0.28% | 93 |
|
|
2021
Q4 | $1.16M | Buy |
10,328
+500
| +5% | +$58.3K | 0.26% | 99 |
|
|
2021
Q3 | $1.1M | Buy |
9,828
+334
| +4% | +$38.1K | 0.24% | 105 |
|
|
2021
Q2 | $1.06M | Sell |
9,494
-50
| -0.5% | -$4.71K | 0.24% | 106 |
|
|
2021
Q1 | $899K | Buy |
9,544
+5,019
| +111% | +$424K | 0.22% | 110 |
|
|
2020
Q4 | $398K | Buy |
4,525
+1,448
| +47% | +$120K | 0.11% | 180 |
|
|
2020
Q3 | $260K | Sell |
3,077
-2,293
| -43% | -$179K | 0.1% | 201 |
|
|
2020
Q2 | $398K | Buy |
5,370
+225
| +4% | +$16K | 0.16% | 137 |
|
|
2020
Q1 | $317K | Buy |
5,145
+36
| +0.7% | +$2.6K | 0.16% | 149 |
|
|
2019
Q4 | $403K | Sell |
5,109
-2,541
| -33% | -$198K | 0.16% | 154 |
|
|
2019
Q3 | $579K | Sell |
7,650
-1,047
| -12% | -$73.5K | 0.26% | 108 |
|
|
2019
Q2 | $623K | Sell |
8,697
-150
| -2% | -$9.07K | 0.28% | 107 |
|
|
2019
Q1 | $526K | Sell |
8,847
-891
| -9% | -$50.8K | 0.24% | 116 |
|
|
2018
Q4 | $565K | Hold |
9,738
| – | – | 0.26% | 117 |
|
|
2018
Q3 | $565K | Buy |
9,738
+1,002
| +11% | +$49K | 0.26% | 119 |
|
|
2018
Q2 | $424K | Sell |
8,736
-177
| -2% | -$8.26K | 0.21% | 137 |
|
|
2018
Q1 | $413K | Buy |
+8,913
| New | +$387K | 0.21% | 130 |
|
Other funds holding EW
180 Wealth Advisors's EW Position: Q2 2026 in Review
180 Wealth Advisors reduced its Edwards Lifesciences (EW) stake by 1.7% in Q2 2026, selling an estimated $25.6K and leaving 17,457 shares worth $1.58M. The position accounts for 0.16% of the portfolio, ranked #141.
180 Wealth Advisors first reported a position in EW in Q1 2018 and has held it in 34 quarters since. 1,328 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- 180 Wealth Advisors held 17,457 shares of Edwards Lifesciences worth $1.58M as of Q2 2026.
- 180 Wealth Advisors sold 305 Edwards Lifesciences shares in Q2 2026, an estimated $25.6K.
- Edwards Lifesciences made up 0.16% of 180 Wealth Advisors's portfolio in Q2 2026, its #141 holding.
- 180 Wealth Advisors first reported a position in Edwards Lifesciences in Q1 2018 and has held it in 34 quarters since.
- 1,328 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.